Management of complicated skin and soft tissue infections in hospitalized patients

U.S. Pharmacist

Volumn 32, Issue 4, 2007, Pages

  Love, Bryan L ^a   Kehr, Heather ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFTOBIPROLE; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DOXYCYCLINE FOSFATEX; ERTAPENEM; GLYCOPEPTIDE; IMIPENEM; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; OXACILLIN; OXYGEN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN; SULTAMICILLIN; TELAVANCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ADD ON THERAPY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIUM CULTURE; BIOEQUIVALENCE; CELLULITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DEBRIDEMENT; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYSIPELAS; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; HYPERBARIC OXYGEN; INFECTION COMPLICATION; INFECTION RISK; INJECTION SITE REACTION; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYOPATHY; NAUSEA; NONHUMAN; PATIENT CARE; PHARMACIST ATTITUDE; PHYSICAL EXAMINATION; POSTOPERATIVE INFECTION; SEIZURE; SIDE EFFECT; SKIN ABSCESS; SOFT TISSUE INFECTION; STREPTOCOCCUS INFECTION; SURGICAL DRAINAGE; THROMBOCYTOPENIA; VOMITING; WOUND HEALING;

EID: 47749144369     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (33)

1. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis. 2001;33(suppl 2):S84-S93.
2. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-1406.
3. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrobial Chemotherapy. 2004;53(suppl)2:ii37-2:ii50.
4. Tice AD, Poretz D, Cook F, et al. Medicare coverage of outpatient ambulatory intravenous antibiotic therapy: a program that pays for itself. Clin Infect Dis. 1998;27:1415-1421.
5. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clinical Microbiology Reviews. 2001;14:244-269.
6. Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrobial Chemotherapy. 2003;52(suppl)1:i3-1:i17.
7. Uncomplicated and complicated skin and skin structure infections - developing antimicrobial drugs for treatment. Guidance for Industry: Center for Drug Evaluation and Research (CDER). 1998. Available at: http://www.fda.gov/cder/guidance/2566dft.pdf.
8. Majeski JA, John JF Jr. Necrotizing soft tissue infections: a guide to early diagnosis and initial therapy. Southern Medical J. 2003;96:900-905.
9. King MD, Humphrey BJ, Wang YF. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Annals of Internal Med. 2006;144:309-317.
10. Jallali N, Withey S, Butler PE. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. American J Surgery. 2005;189:462-466.
11. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/ dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrobial Chemotherapy. 1999;44:263-273.
12. Delgado G Jr, Neuhauser MM, Bearden DT. Quinupristin-dalfopristin: an overview. Pharmacotherapy. 2000;20:1469-1485.
13. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Anna Intern Med. 2003;138:135-142.
14. Sharpe JN, Shively EH, Polk HC, Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. American J Surgery. 2005;189:425-428.
15. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy. 2005;49:2260-226.
16. Donowitz GR. Oxazolidinones. In: Mandell GL, Douglas RG, Bennett JE, Dolin R, eds. Mandell, Dougals, and Bennett's Principles and Practice of Infectious Diseases. 6th ed. New York, NY: Elsevier/Churchill Livingstone; 2005:436-440.
17. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy. 2000;44:3408-3413.
18. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs. 2005;65:2151-2178.
19. Chambers HF. Other B-lactam antibiotics. In: Mandell GL, Douglas RG, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th ed. New York: Elsevier/ Churchill Livingstone; 2005:311-318.
20. Tellado J, Woods GL, Gesser R, et al. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections. Surgical infections. 2002;3:303-314.
21. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:994-1000.
22. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrobial Chemotherapy. 2005;55:283-238.
23. Murray BE, Nannini EC. Glycopeptides (vancomycin, teicoplanin), streptogramins (quinupristin-dalfopristin), and lipopeptides (daptomycin). In: Mandell GL, Douglas RG, Bennett JE, Dolin R, eds. Mandell, Dougals, and Bennett's Principles and Practice of Infectious Diseases. 6th ed. New York, NY: Elsevier/Churchill Livingstone; 2005:417-434.
24. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-1681.
25. Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ. Tigecycline: a novel glycylcycline antibiotic. Expert Review of Anti-infective Therapy. 2006;4:9-25.
26. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clinical Therapeutics. 2006;28:1079-1106.
27. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrobial Agents and Chemotherapy. 2005;49:4658-4566.
28. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41(suppl 5): S341-S353.
29. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005;9:251-261.
30. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407-1415.
31. Seltzer E, Dorr MB, Goldstein BP, Perry M, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37:1298-1303.
32. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40:1601-1607.
33. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrobial Agents and Chemotherapy. 2006;50:862-867.